Sat, Apr 19, 2014, 4:11 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • la_lost_boy la_lost_boy Aug 15, 2013 9:00 PM Flag

    Extremely positive P3 trial results

    What more could anyone had hoped for?
    Sell off = buying opportunity

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • For instance, type 1 diabetics in the Afrezza group failed to hit the key target A1c levels, a long-term measure of blood sugar levels. Doctors like to see patients get their A1c levels below 7%, but the portion of the patients who reached the target was higher in the group taking Novo Nordisk's (NYSE: NVO ) injected insulin Novolog than the Afrezza group. The proportion getting under 6.5% also favored the Novolog group.

      BAD

      The number of severe hypoglycemia events, extremely low blood sugar, in type 1 diabetics was lower in the Afrezza group than those taking Novolog, but it wasn't statistically significant, so MannKind won't be able to tout it as an advantage.

      BAD

      In type 2 diabetics, Afrezza caused more hypoglycemic events than the placebo, which isn't all that surprising, but will clearly be a factor for whether doctors are willing to prescribe it earlier in the disease progression than they would Novolog or Eli Lilly's (NYSE: LLY ) injected insulin Humalog.

      BAD

      Patients taking placebo also lost more weight than the group taking Afrezza

      BAD

      - but the data might not be convincing enough to justify the early use of Afrezza.

      BAD

      TO MUCH BAD TO RAISE PPS MORE

 
MNKD
6.25-0.14(-2.19%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.